Diabetes

Findings from the FLOW trial, the first dedicated kidney outcomes trial with semaglutide in patients with Type 2 diabetes and chronic kidney disease, were presented at EASD 2024.

New analysis from the SURPASS-4 trial identifies crucial factors for maintaining blood glucose control and weight loss with tirzepatide in patients with Type 2 diabetes.

A key study presented at EASD 2024 highlights that rapidly managing blood sugar in pregnant women with gestational diabetes reduces the risk of obesity in their children.

Time-restricted eating, limiting food intake to an 8-hour window, significantly improves blood sugar control in adults at risk of Type 2 diabetes, research from EASD 2024 shows.

The SCALE Kids trial has found that weight-loss drug liraglutide is safe and effective for children aged 6 to under 12 years living with obesity.

A study has confirmed a significant link between a diet that includes meat consumption and the risk of developing type 2 diabetes.

A new study has highlighted the strong bidirectional relationship between chronic diabetes complications and mental health disorders in individuals with diabetes.

A recent cohort study has highlighted the potential of tirzepatide to significantly improve clinical outcomes in patients with Type 2 diabetes.